CSIMarket Company Name, Ticker, Industry, else..
 
Avidity Biosciences Inc   (NASDAQ: RNA)
Other Ticker:  
 
 
Price: $29.6700 $-0.46 -1.527%
Day's High: $30.125 Week Perf: 2.59 %
Day's Low: $ 29.23 30 Day Perf: -6.76 %
Volume (M): 1,128 52 Wk High: $ 56.00
Volume (M$): $ 33,465 52 Wk Avg: $33.90
Open: $29.72 52 Wk Low: $10.30



 Market Capitalization (Millions $) 3,661
 Shares Outstanding (Millions) 123
 Employees 136
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -262
 Cash Flow (TTM) (Millions $) 219
 Capital Exp. (TTM) (Millions $) 5

Avidity Biosciences Inc
Avidity Biosciences Inc is a biotechnology company focused on the development of antibody-based therapeutics. Using its proprietary AOC technology, the company aims to create novel therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Avidity Biosciences combines the high specificity of antibodies with the precision of small molecules to deliver therapeutics that can efficiently target specific cells or tissues. By leveraging its innovative platform, the company aims to revolutionize the treatment of various diseases and improve patient outcomes.


   Company Address: 10578 Science Center Drive San Diego 92121 CA
   Company Phone Number: 401-7900   Stock Exchange / Ticker: NASDAQ RNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY      % 
CORT      % 
PFE      % 
REGN      % 
SRPT      % 
VRTX      % 
• View Complete Report
   



Stocks on the Move

Avidity Biosciences Inc Assessing the Factors Behind Recent Stock Fluctuations and Future Potential

Published Tue, Jul 9 2024 10:23 AM UTC

Avidity Biosciences Inc, a biopharmaceutical company focused on developing RNA-based therapies, has experienced mixed performance in its stock value this year. While some instances have seen a decline, key breakthroughs and positive evaluations have also caused the stock to surge. In this article, we will explore the reasons behind Avidity Biosciences stock fluctuations and...
Stocks on the Move

Avidity Biosciences Harnesses RNA Therapeutics to Transform Biopharmaceutical Landscape

Published Fri, Jun 28 2024 2:08 PM UTC

In recent news, Avidity Biosciences, a pioneering biopharmaceutical company, has made significant strides in its mission to revolutionize the treatment landscape through its innovative RNA therapeutics platform. Avidity Biosciences is committed to developing Antibody Oligonucleotide Conjugates (AOCstm), a novel class of therapeutics that hold immense potential in targeting d...
Stocks on the Move

Avidity Biosciences Inc. Growing Momentum in Biopharmaceutical Innovation

Published Thu, Jun 27 2024 10:15 AM UTC

In recent weeks, Avidity Biosciences Inc. (NASDAQ: RNA) has made significant headway in the biopharmaceutical industry, positioning itself as a leader in the field of RNA therapeutics. The company s commitment to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs) has garnered attention from investors and industry experts alike. With ...
Avidity Biosciences Inc

RNA's Widening Deficit Raises Concerns for Avidity Biosciences Inc in Latest Fiscal Quarter



Avidity Biosciences Inc, a prominent player in the Major Pharmaceutical Preparations sector, has showcased substantial improvements in its financial performance and market positioning. Despite reporting a deficit per share in the recent fiscal period, the company's revenue has witnessed an impressive surge, outperforming its sector peers. Moreover, Avidity Biosciences Inc shares have been on an upward trajectory, indicating positive investor sentiment and potential future gains.
Financial Performance:
In the most recent fiscal period, Avidity Biosciences Inc experienced an increase in the deficit per share, amounting to $-0.79 compared to $-0.74 recorded a year ago. Additionally, the company's deficit grew from $-0.62 per share from the previous reporting period. It is essential to note that deficits are generally anticipated for growing biotech firms investing heavily in research and development.
Avidity Biosciences Inc

Avidity Biosciences Inc. Faces Challenges with Declining Returns in Fourth Quarter of 2023 Earnings Season

The financial results for the fourth quarter of 2023 paint a mixed picture for Avidity Biosciences Inc. On one hand, the company was able to decrease its loss per share from the previous year, showing some improvement in its financial performance. However, the significant decrease in revenue by over 20% is concerning and indicates a potential struggle for the company to generate revenue.
The net deficit for the quarter also increased compared to the previous year, which is a red flag for investors and stakeholders. The company also reported a significant shortfall in RNA of over $212 million, which may affect its ability to fund research and development activities. With a total revenue of $9.56 million for the fiscal period, it seems that Avidity Biosciences Inc. may be facing challenges in generating sustainable revenue streams.






Avidity Biosciences Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com